Determinants of protective immunity against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection require the development of well-standardized, reproducible …

Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated
with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of …

Background The literature on first generation COVID-19 vaccines show they were less effective
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …

Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …

Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN)
702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. …

… Walsh, MD, 3, * Aiying Chen, PhD, 1 Nicole Grunenberg, MD, 4 Mary Allen, MS, 5
Johannes Antony, PhD, 6 Kwaku Poku Asante, PhD, 7 Amit Suresh Bhate, MD, 8 Tatiana …

Determinants of protective immunity against SARS-CoV-2 infection require the development
of well-standardized, reproducible antibody assays to be utilized in concert with clinical …

Importance SARS-CoV-2 viral load (VL) in the nasopharynx is difficult to quantify and
standardize across settings, but it may inform transmission potential and disease severity. …

Amino acid substitution matrices are commonly used for sequence alignment, phylogenetic
inference and sequence comparison. Empirical organism-specific substitution matrices …

Background. Pritelivir is a novel helicase-primase inhibitor in clinical development for
treatment of herpes simplex virus type 2 (HSV-2) infections. In preclinical work, resistance-…